Epitope-specific tolerance induction with an engineered immunoglobulin.
about
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsBeyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologicsReduced antibody response to streptavidin through site-directed mutagenesisNeonatal tolerant immunity for vaccination against autoimmunity.Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.Inhibitors - cellular aspects and novel approaches for tolerance.Gene therapeutic approaches to induction and maintenance of tolerance."Troy-bodies": recombinant antibodies that target T cell epitopes to antigen presenting cells.B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAEInduction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsivenessRecombinant immunoglobulin-based epitope delivery: a novel class of autoimmune regulators.Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processingNeonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergyTregitopes switch on Tregs.B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathwayAntigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.Activated B cells in autoimmune diseases: the case for a regulatory role.Tregitope peptides: the active pharmaceutical ingredient of IVIG?Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Potential application of tregitopes as immunomodulating agents in multiple sclerosis.New therapies for hemophilia.Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytesFrom IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules.Immunogenicity of Therapeutic Fusion Proteins: Contributory Factors and Clinical Experience
P2860
Q24651243-025EE792-9AB6-47B3-8245-8C80FAC40CD2Q26822421-F85943EE-0F23-4DEA-AC37-6F9DFD558DE5Q26826924-A3B1E2CD-FD60-4296-B964-DF0D30DD231CQ28364576-2B1CFA10-F3AA-428C-8566-8B890F5B0829Q33891071-DCC13707-4715-416E-9720-D0396B00639BQ34348211-B8B07881-9F8E-4BEF-A11B-4CAB63C97B73Q34380850-4BF28EDC-0660-4CCA-A122-20593317AD08Q34560532-A391E805-0806-406E-89A0-53F589380B68Q34560537-92A36592-269D-45CB-9788-AC7952C915F2Q35172788-3C25696F-5912-4C89-9D73-5F75FF245A43Q35557554-FE55693B-57D7-4B03-BD00-0ACC9632FF25Q36327391-F932BC0D-3074-44BC-9465-E953D48F4FA7Q36376999-53338C19-ADB9-401E-B8E7-80FCA20956C8Q36401218-C8CEB3AB-6E90-4C1A-8F8F-CF6AECE73C04Q36941022-A2AFC41D-C6B8-40FC-8F3B-4AD488D8D0F4Q36983280-4FC987CA-EDA2-4A95-9A80-9E22CEB33A90Q37051562-16475C19-03C1-487C-A362-DDB9DCD3215AQ37335863-62ADBC7A-32B1-4303-AAA7-1E50BDB60F45Q37456938-99B9F148-9F44-4EB7-B95E-DB4CEA1D3F06Q37522009-BD820894-C7B3-407B-A057-7791661D9CCFQ37782256-1134B106-E7B7-46BE-B209-29749569268FQ38039963-09C87ED8-45FE-47DA-91CA-5EBACA69F560Q38133405-A8AE2722-FD3D-4E0C-94E9-0E2BFE993587Q38501673-1E8D119B-34D9-4421-AE1E-5B09958CA4BDQ39027887-30E3309E-ACF9-4AC4-BF89-0DA3567C3BB4Q41941128-DD214144-EB16-4C9F-B832-CD064E7F7B8FQ45875104-6FBEF692-AC60-4432-BD7F-12A20CADDCADQ45877596-9ECF48B7-84AC-4F07-A550-A4C7A22A0F08Q45881605-ACE7CEF9-13D1-47F7-95FB-E21410E65502Q57537530-6911A6C5-C164-4716-8390-1C7623C4DA6C
P2860
Epitope-specific tolerance induction with an engineered immunoglobulin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epitope-specific tolerance induction with an engineered immunoglobulin.
@en
Epitope-specific tolerance induction with an engineered immunoglobulin.
@nl
type
label
Epitope-specific tolerance induction with an engineered immunoglobulin.
@en
Epitope-specific tolerance induction with an engineered immunoglobulin.
@nl
prefLabel
Epitope-specific tolerance induction with an engineered immunoglobulin.
@en
Epitope-specific tolerance induction with an engineered immunoglobulin.
@nl
P2860
P356
P1476
Epitope-specific tolerance induction with an engineered immunoglobulin.
@en
P2093
E T Zambidis
P2860
P304
P356
10.1073/PNAS.93.10.5019
P407
P577
1996-05-01T00:00:00Z